Want to see DE:SBS full AI Analyst Report?
SBS Stock Chart & Stats
€24.30
€0.28(1.42%)
At close: 4:00 PM EDT
€24.30
€0.28(1.42%)
Day’s Range― - ―
52-Week Range€16.30 - €33.10
Previous CloseN/A
Volume3.37K
Average Volume (3M)11.85K
Market Cap
€294.78M
Enterprise Value€300.91
Total Cash (Recent Filing)€19.03M
Total Debt (Recent Filing)€115.72M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Nov 12, 2026EPS Estimate
0.23Next Dividend Ex-DateN/A
Dividend Yield2.47%
Share Statistics
EPS (TTM)-0.04
Shares Outstanding12,157,841
10 Day Avg. Volume10,846
30 Day Avg. Volume11,851
Financial Highlights & Ratios
PEG Ratio11.11
Price to Book (P/B)1.15
Price to Sales (P/S)1.09
P/FCF Ratio-28.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€29.00Price Target Upside19.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.45
Revenue Forecast (FY)€267.07M
Bulls Say, Bears Say
Bulls Say
Systems Revenue GrowthStrong systems growth shows continued demand for STRATEC’s core diagnostic platforms across immunoassay, molecular diagnostics and immunohematology. This supports customer relationships, future production volumes and the company’s longer-term growth trajectory.
Cash Generation And Lower LeverageThe sharp cash-flow rebound and debt reduction improve financial flexibility and reduce balance-sheet risk. Positive free cash flow can support investment in platforms and lifecycle services while giving management greater capacity to manage operating volatility.
Regulatory-driven Lifecycle DemandRegulatory and cybersecurity requirements create ongoing customer needs for product updates, documentation, software and sustaining engineering. STRATEC’s lifecycle capabilities can therefore generate durable service opportunities beyond initial instrument development and production.
Bears Say
Revenue Contraction And Thin ProfitabilitySeveral years of revenue contraction have materially weakened earnings quality, leaving operating profit thin and the bottom line near break-even. This limits internally funded growth and makes margin recovery dependent on a sustained improvement in demand and product mix.
Weak Consumables And Maintenance DemandWeak service-parts and consumables demand pressures a recurring revenue stream and reduces the contribution from installed platforms. Customer inventory optimization and M&A-related working-capital actions may persist, making recovery less certain over the next several quarters.
Softer Molecular Diagnostics MarketA flatter molecular-diagnostics market reduces the growth opportunity for an important part of STRATEC’s systems business. Lower industry expansion can constrain customer platform launches, production volumes and the pace at which the company achieves its medium-term targets.
STRATEC Biomedical News
SBS FAQ
What was STRATEC Biomedical AG’s price range in the past 12 months?
STRATEC Biomedical AG lowest stock price was €16.30 and its highest was €33.10 in the past 12 months.
What is STRATEC Biomedical AG’s market cap?
STRATEC Biomedical AG’s market cap is €294.78M.
When is STRATEC Biomedical AG’s upcoming earnings report date?
STRATEC Biomedical AG’s upcoming earnings report date is Nov 12, 2026 which is in 52 days.
How were STRATEC Biomedical AG’s earnings last quarter?
STRATEC Biomedical AG released its earnings results on Aug 14, 2026. The company reported €0.385 earnings per share for the quarter, beating the consensus estimate of €0.19 by €0.195.
Is STRATEC Biomedical AG overvalued?
According to Wall Street analysts STRATEC Biomedical AG’s price is currently Undervalued.
Does STRATEC Biomedical AG pay dividends?
STRATEC Biomedical AG pays a Annually dividend of €0.6 which represents an annual dividend yield of 2.47%. See more information on STRATEC Biomedical AG dividends here
What is STRATEC Biomedical AG’s EPS estimate?
STRATEC Biomedical AG’s EPS estimate is 0.23.
How many shares outstanding does STRATEC Biomedical AG have?
STRATEC Biomedical AG has 12,157,841 shares outstanding.
What happened to STRATEC Biomedical AG’s price movement after its last earnings report?
STRATEC Biomedical AG reported an EPS of €0.385 in its last earnings report, beating expectations of €0.19. Following the earnings report the stock price went up 9.181%.
Which hedge fund is a major shareholder of STRATEC Biomedical AG?
Currently, no hedge funds are holding shares in DE:SBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
STRATEC Biomedical Stock Smart Score
Company Description
STRATEC Biomedical AG
Established in 1979 and headquartered in Birkenfeld, Germany, Stratec SE (previously known as STRATEC Biomedical AG until its name change in December 2018) specializes in the development and manufacturing of cutting-edge automation and instrumentation systems. The company caters to the in-vitro diagnostics and life sciences sectors, operating across Germany, the European Union, and globally. Its business is divided into three primary segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment focuses on designing and fabricating automated analytical systems, along with necessary spare parts and supplies, for customers in clinical diagnostics and biotechnology. The Diatron segment provides a suite of systems, components, disposables, and assays for lower-volume hematology and clinical chemistry applications. Finally, the Smart Consumables segment is dedicated to engineering and producing intelligent consumables for the diagnostics, life sciences, and medical technology industries.
SBS Stock 12 Month Forecast
Average Price Target
€29.00
▲(19.34% Upside)
Technical Analysis
Draegerwerk AG & Co. KGaA
―
Eckert & Ziegler Strahlen und Medizintechnik
―
First Sensor
―
Gerresheimer
―
Siemens Healthineers AG
―